Search results for "MYOPATHY"

showing 10 items of 352 documents

Procedural, Functional and Prognostic Outcomes Following Recanalization of Coronary Chronic Total Occlusions. Results of the Iberian Registry.

2019

Introduction and objectives: There is current controversy regarding the benefits of percutaneous recanalization (PCI) of chronic total coronary occlusions (CTO). Our aim was to determine acute and follow-up outcomes in our setting. Methods: Two-year prospective registry of consecutive patients undergoing PCI of CTO in 24 centers. Results: A total of 1000 PCIs of CTO were performed in 952 patients. Most were symptomatic (81.5%), with chronic ischemic heart disease (59.2%). Previous recanalization attempts had been made in 15%. The mean SYNTAX score was 19.5 +/- 10.6 and J-score was > 2 in 17.3%. A retrograde procedure was performed in 92 patients (9.2%). The success rate was 74.9% and was hi…

MaleReoperationmedicine.medical_specialtyPercutaneousmedicine.medical_treatmentPerforation (oil well)Myocardial Ischemia030204 cardiovascular system & hematology03 medical and health sciencesPercutaneous Coronary InterventionPostoperative Complications0302 clinical medicineInternal medicineMyocardial RevascularizationmedicineHumansProspective StudiesRegistriesMyocardial infarctionProspective cohort studyUltrasonography InterventionalAgedPortugalbusiness.industryMortality ratePercutaneous coronary interventionGeneral Medicinemedicine.diseaseTreatment OutcomeCoronary OcclusionSurgery Computer-AssistedSpainCoronary occlusionChronic DiseaseConventional PCICardiologyFemaleCTO Cardiopatía isquémica crónica Chronic ischemic cardiomyopathy Chronic total occlusions IVUS OCT Oclusiones crónicasbusiness
researchProduct

Gender differences in takotsubo syndrome

2022

Background: Male sex in takotsubo syndrome (TTS) has a low incidence and it is still not well characterized. Objectives: The aim of the present study is to describe TTS sex differences. Methods: TTS patients enrolled in the international multicenter GEIST (GErman Italian Spanish Takotsubo) registry were analyzed. Comparisons between sexes were performed within the overall cohort and using an adjusted analysis with 1:1 propensity score matching for age, comorbidities, and kind of trigger. Results: In total, 286 (11%) of 2,492 TTS patients were men. Male patients were younger (age 69 ± 13 years vs 71 ± 11 years; P = 0.005), with higher prevalence of comorbid conditions (diabetes mellitus 25% …

MaleSex Characteristicsmale sexcardiogenic shockShock CardiogenicSexotakotsuboChoque cardiogénicoSex FactorsTakotsubo CardiomyopathyPrevisiónfollow-upgenderHumansFemaleCardiomiopatía de TakotsuboprognosisRegistriesCardiology and Cardiovascular MedicineSistema cardiovascular
researchProduct

Monitoring effectiveness and safety of Tafamidis in transthyretin amyloidosis in Italy: a longitudinal multicenter study in a non-endemic area

2016

Tafamidis is a transthyretin (TTR) stabilizer able to prevent TTR tetramer dissociation. There have been a few encouraging studies on Tafamidis efficacy in early-onset inherited transthyretin amyloidosis (ATTR) due to Val30Met mutation. However, less is known about its efficacy in later disease stages and in non-Val30Met mutations. We performed a multi-center observational study on symptomatic ATTR patients prescribed to receive Tafamidis. We followed up patients according to a standardized protocol including general medical, cardiological and neurological assessments at baseline and every 6 months up to 3 years. Sixty-one (42 males) patients were recruited. Only 28 % of enrolled subjects h…

MaleTafamidisAmyloid polyneuropathyNeurologyCardiomyopathyDisease030204 cardiovascular system & hematologySeverity of Illness IndexTransthyretinchemistry.chemical_compound0302 clinical medicinePrealbuminTafamidiLongitudinal StudiesStage (cooking)Aged 80 and overBenzoxazolesbiologyAmyloidosisMiddle Agedamyloid polyneuropathy; tafamidis; transthyretinPrognosisTafamidisSettore MED/26 - NEUROLOGIATreatment OutcomeItalyNeurologyDisease ProgressionFemaleAmyloid polyneuropathy; Tafamidis; Transthyretin; Neurology (clinical); NeurologyAdultmedicine.medical_specialty03 medical and health sciencesInternal medicineSeverity of illnessmedicineHumansAgedAmyloid Neuropathies Familialbusiness.industrynutritional and metabolic diseasesmedicine.diseaseSurgeryTransthyretinchemistryMutationbiology.proteinNeurology (clinical)business030217 neurology & neurosurgeryFollow-Up StudiesJournal of Neurology
researchProduct

A putative placebo analysis of the effects of LCZ696 on clinical outcomes in heart failure

2015

Aims: Although active-controlled trials with renin–angiotensin inhibitors are ethically mandated in heart failure with reduced ejection fraction, clinicians and regulators often want to know how the experimental therapy would perform compared with placebo. The angiotensin receptor-neprilysin inhibitor LCZ696 was compared with enalapril in PARADIGM-HF. We made indirect comparisons of the effects of LCZ696 with putative placebos.\ud \ud Methods and results: We used the treatment-arm of the Studies Of Left Ventricular Dysfunction (SOLVD-T) as the reference trial for comparison of an ACE inhibitor to placebo and the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidit…

MaleTetrazolesAngiotensin-Converting Enzyme InhibitorsEnalaprilEnalapril/therapeutic useMedicineNatriuretic peptidesAngiotensin IIAminobutyratesHeart Failure/CardiomyopathyMiddle AgedAngiotensin Receptor Antagonists/therapeutic useHospitalizationAngiotensin-Converting Enzyme Inhibitors/therapeutic useDrug CombinationsTreatment OutcomeTetrazoles/therapeutic useCardiologyValsartanFemaleCardiology and Cardiovascular Medicinemedicine.drugBenzimidazoles/therapeutic usemedicine.medical_specialtyAngiotensin II Type 1 Receptor Blockers/therapeutic usemedicine.drug_classPlaceboAngiotensin Receptor AntagonistsInternal medicineHumansEnalaprilFASTTrack Clinical ResearchBeta blockerAgedHospitalization/statistics & numerical dataHeart Failurebusiness.industryBiphenyl Compoundsmedicine.diseaseHeart Failure/drug therapyPlacebo EffectAngiotensin IICandesartanEndocrinologyAminobutyrates/therapeutic useHeart failureACE inhibitorBenzimidazolesbusinessAngiotensin II Type 1 Receptor BlockersSacubitril ValsartanNatriuretic peptide
researchProduct

Pilot study of safety and efficacy of polyprenols in combination with coenzyme Q10 in patients with statin-induced myopathy

2016

Background and objective: Statin-induced myopathy (SIM) has been partially attributed to deficiency of dolichol and coenzyme Q10 (CoQ10). We aimed to test the safety and efficacy of plant polyprenols in combination with CoQ10 for alleviation of SIM. Materials and methods: In an open-label, one-center prospective pilot study patients with SIM received conifer-tree needle polyprenols (4 mg/day) and CoQ10 (100 mg/day) for 8 weeks. Symptoms and safety were evaluated according to symptom severity score (0–10), creatine kinase (CK) levels, exercise test, dynamometry, complete blood count, clinical biochemistry and electrocardiography. Results: Of the 14 patients, 11 completed the study per protoc…

MaleUbiquinoneMyopathyPilot Projects030204 cardiovascular system & hematologyGastroenterologyElectrocardiography0302 clinical medicine030212 general & internal medicineProspective StudiesProspective cohort studyPain MeasurementAged 80 and overMedicine(all)lcsh:R5-920Muscle Weaknessbiologymedicine.diagnostic_testComplete blood countMiddle AgedTreatment OutcomeDrug Therapy CombinationFemalemedicine.symptomlcsh:Medicine (General)Glomerular Filtration Ratemedicine.medical_specialtyStatinmedicine.drug_classRenal functionAsymptomaticPolyprenols03 medical and health sciencesDouble-Blind MethodInternal medicinemedicineHumansMyopathyAgedbusiness.industryTerpenesStatinsMyalgiamedicine.diseaseTracheophytaAutomotive EngineeringPhysical therapybiology.proteinExercise TestCoenzyme Q10Creatine kinaseHydroxymethylglutaryl-CoA Reductase InhibitorsbusinessStatins; Myopathy; Polyprenols; Coenzyme Q10; UbiquinoneBiomarkersKidney diseaseMedicina
researchProduct

HACD1, a regulator of membrane composition and fluidity, promotes myoblast fusion and skeletal muscle growth

2015

International audience; The reduced diameter of skeletal myofibres is a hallmark of several congenital myopathies, yet the underlying cellular and molecular mechanisms remain elusive. In this study, we investigate the role of HACD1/PTPLA, which is involved in the elongation of the very long chain fatty acids, in muscle fibre formation. In humans and dogs, HACD1 deficiency leads to a congenital myopathy with fibre size disproportion associated with a generalized muscle weakness. Through analysis of HACD1-deficient Labradors, Hacd1-knockout mice, and Hacd1-deficient myoblasts, we provide evidence that HACD1 promotes myoblast fusion during muscle development and regeneration. We further demons…

Male[SPI.GPROC] Engineering Sciences [physics]/Chemical and Process EngineeringCellular differentiationGeneralized muscle weaknessBiologyMuscle Developmentcentronuclear myopathyCell LineMyoblasts03 medical and health scienceschemistry.chemical_compoundMyoblast fusionMice0302 clinical medicineDogsVLCFA[SDV.IDA]Life Sciences [q-bio]/Food engineeringGeneticsmedicineMyocyteAnimalsHumans[SPI.GPROC]Engineering Sciences [physics]/Chemical and Process EngineeringMUFACentronuclear myopathyMuscle SkeletalMolecular Biology030304 developmental biologyMice Knockout0303 health sciencesPTPLACell MembraneSkeletal muscleCell DifferentiationCell BiologyGeneral MedicineArticles[SDV.IDA] Life Sciences [q-bio]/Food engineeringmedicine.diseaseCongenital myopathyLysophosphatidylcholinemedicine.anatomical_structureLPCchemistryBiochemistryFemaleProtein Tyrosine Phosphatasescentronuclear myopathy;lpc;mufa;ptpla;vlcfa030217 neurology & neurosurgery
researchProduct

Long-term LVEF trajectories in patients with type 2 diabetes and heart failure: diabetic cardiomyopathy may underlie functional decline

2020

Abstract Background Left ventricular ejection fraction (LVEF) trajectories and functional recovery with current heart failure (HF) management is increasingly recognized. Type 2 diabetes mellitus (T2D) leads to a worse prognosis in HF patients. However, it is unknown whether T2D interferes with LVEF trajectories. The aim of this study was to prospectively assess very long-term (up to 15 years) LVEF trajectories in patients with and without T2D and underlying HF. Methods Ambulatory patients admitted to a multidisciplinary HF clinic were prospectively evaluated by scheduled two-dimensional echocardiography at baseline, 1 year, and then every 2 years afterwards, up to 15 years. Statistical anal…

Malelcsh:Diseases of the circulatory (Cardiovascular) systemmedicine.medical_specialtyEjection fractionTime FactorsEtiologyDiabetic CardiomyopathiesEndocrinology Diabetes and MetabolismHeart failureType 2 diabetesVentricular Function LeftVentricular Dysfunction LeftDiabetes mellitusLong-termRisk FactorsInternal medicineDiabetes mellitusDiabetic cardiomyopathymedicineHumansProspective StudiesOriginal InvestigationAngiologyAgedHeart FailureEjection fractionbusiness.industryFollow-upType 2 Diabetes MellitusStroke VolumeMiddle Agedmedicine.diseaseProgression-Free SurvivalDiabetes Mellitus Type 2lcsh:RC666-701Heart failureAmbulatoryDisease ProgressionFemaleCardiology and Cardiovascular Medicinebusiness
researchProduct

Ventricular dysfunction and number of non compacted segments in non compaction: Non-independent predictors.

2010

Abstract Background Isolated ventricular noncompaction (IVNC) is characterized by multiple prominent trabeculations and deep intertrabecular recesses. Some reports prove that the chronic heart failure may occur in approximately half of the patients. In this report we investigate the correlation between the number of non compacted segments and entity of systolic dysfunction from the registry and subregistries of the SIEC. Method To identify the correlation between ventricular dysfunction and number of segments involved in non compaction we evaluated a consecutive series of 238 patients affected by non compaction, from the SIEC (Societa Italiana di Ecografia Cardiovascolare) registry. The ave…

Malemedicine.medical_specialtyAdolescentCardiomyopathyVentricular non compactionDiastoleCardiomyopathyProminent trabeculationsSeverity of Illness IndexNOVentricular Dysfunction LeftYoung AdultPredictive Value of TestsInternal medicinemedicineHumansRegistriesChildVentricular dysfunctionAgedVentricular non compaction; Cardiomyopathy; Ventricular dysfunction; Number of segments; Compact/spongy ratioAged 80 and overIsolated Noncompaction of the Ventricular Myocardiumbusiness.industryCompact/spongy ratioInfantMiddle Agedmedicine.diseaseNumero signPredictive factorSurgeryHeart failureChild PreschoolCardiologyNumber of segmentsFemaleMyocardial diseaseCardiology and Cardiovascular MedicinebusinessCardiomyopathy; Number of segments Compact/spongy ratio; Ventricular dysfunction; Ventricular non compactionHeart Failure Systolic
researchProduct

Prophylactic Implantable Cardioverter Defibrillator Placement in a Sporadic Desmin Related Myopathy and Cardiomyopathy

2004

Desminopathy is a neuromuscular disorder associated with the accumulation of the protein desmin. This article reports a case of a man with a mutation in the desmin gene suffering from cardiomyopathy and skeletal myopathy. This patient underwent implantable cardioverter defibrillator (ICD) implantation for prognostic considerations and subsequently developed a sustained ventricular tachycardia (SVT). While nonsustained VTs (NSVT) have previously been reported, this is the first time that a SVT could be seen in a patient with this disease.

Malemedicine.medical_specialtyAdolescentmedicine.medical_treatmentCardiomyopathyDiseaseDesminInternal medicineHumansMedicineDESMIN-RELATED MYOPATHYbusiness.industryImplantable Cardioverter-Defibrillator PlacementGeneral MedicineImplantable cardioverter-defibrillatormedicine.diseaseSkeletal myopathyDefibrillators ImplantableSustained ventricular tachycardiaMutationTachycardia VentricularCardiologyDesminCardiomyopathiesCardiology and Cardiovascular MedicinebusinessMyopathies Structural CongenitalPacing and Clinical Electrophysiology
researchProduct

Evidence of impaired coronary flow reserve and elevated microvascular resistances in a case of recurrent left apical ballooning.

2011

A 56-year old man was admitted for precordial pain associated with dyspnea and evidence of myocardial ischemia on ECG and cardiac ultrasound. His previous history included an episode of left apical ballooning five years before. At angiography, no evidence of significant epicardial coronary artery disease was manifest. Interestingly, both coronary flow reserve and the index of microvascular resistances were abnormal, showing evidence of impaired microvascular function. This is the first report providing direct evidence of microvascular dysfunction in a patient with (recurrent) apical ballooning.

Malemedicine.medical_specialtyApical ballooningMyocardial ischemiamedicine.diagnostic_testbusiness.industryEpicardial coronary arteryCoronary flow reserveMiddle AgedCardiac UltrasoundPrecordial painTakotsubo CardiomyopathyInternal medicineCoronary CirculationAngiographyMicrovesselsmedicineCardiologyHumansVascular ResistanceCardiology and Cardiovascular MedicinebusinessInternational journal of cardiology
researchProduct